Survey of Ophthalmology
Volume 47 , Pages S90-S96 , August 2002

The Effect of Latanoprost on Circadian Intraocular Pressure

  • Lill-Inger Larsson, MD, PhD

      Affiliations

    • Corresponding Author InformationReprint address: Lill-Inger Larsson, MD, PhD, Department of Ophthalmology, Uppsala University Hospital, S-751 85 Uppsala, Sweden.
    • Department of Ophthalmology, Uppsala University Hospital, Uppsala, Sweden
    • ,
  • Hiromu K Mishima, MD

      Affiliations

    • Department of Ophthalmology, Hiroshima University School of Medicine, Hiroshima, Japan
    • ,
  • Michiya Takamatsu, MD

      Affiliations

    • Department of Ophthalmology, Hiroshima University School of Medicine, Hiroshima, Japan
    • ,
  • Nicola Orzalesi, MD

      Affiliations

    • Eye Clinic, Institute of Biomedical Sciences, San Paolo Hospital, University of Milan, Milan, Italy
    • ,
  • Luca Rossetti, MD

      Affiliations

    • Eye Clinic, Institute of Biomedical Sciences, San Paolo Hospital, University of Milan, Milan, Italy

References 

  1. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743–1752
  2. Alm A, Widengard I, Kjellgren D, et al.  Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995;79:12–16
  3. Bito LZ. The impact of intraocular pressure on venous outflow from the globe (a hypothesis regarding IOP-dependent vascular damage in normal-tension and hypertensive glaucoma). J Glaucoma. 1995;5:127–134
  4. Bito LZ. Glaucoma (a physiologic perspective with Darwinian overtones). J Glaucoma. 1992;1:193–205
  5. Brown B, Burton P, Mann S, Parisi A. Fluctuations in intra-ocular pressure with sleep (II. Time course of IOP decrease after waking from sleep). Ophthalmic Physiol Opt. 1988;8:249–252
  6. Brown B, Morris P, Muller C, et al.  Fluctuations in intra-ocular pressure with sleep (I. Time course of IOP increase after the onset of sleep). Ophthalmic Physiol Opt. 1988;8:246–248
  7. Brubaker RF. Delayed functional loss in glaucoma. LII Edward Jackson memorial lecture. Am J Ophthalmol. 1996;121:473–483
  8. Buguet A, Py P, Romanet JP. 24-hour (nyctohemeral) and sleep-related variations of intraocular pressure in healthy white individuals. Am J Ophthalmol. 1994;117:342–347
  9. Drance SM. The significance of the diurnal tension variations in normal and glaucomatous eyes. Arch Ophthalmol. 1960;64:494–501
  10. Ericson LA. Twenty-four hourly variations of the aqueous flow. Acta Ophthalmol. 1958;36(Suppl):1–95
  11. Frampton P, Da Rin D, Brown B. Diurnal variation of intraocular pressure and the overriding effects of sleep. Am J Optom Physiol Opt. 1987;64:54–61
  12. Graham SL, Drance SM, Wijsman K, et al.  Ambulatory blood pressure monitoring in glaucoma. The nocturnal dip. Ophthalmology. 1995;102:61–69
  13. Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol. 1994;117:603–624
  14. Ingram CJ, Brubaker RF. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol. 1999;128:292–296
  15. Kiuchi Y, Takamatsu M, Mishima HK. PhXA41, a prostaglandin F2-analogue reduces the intraocular pressure (IOP) in human volunteers during day and night. Invest Ophthalmol Vis Sci. 1994;35(Suppl):2178; [abstract]
  16. Konstas AG, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol. 1997;115:182–185
  17. Krag S, Andersen HB, Sorensen T. Circadian intraocular pressure variation with beta-blockers. Acta Ophthalmol Scand. 1999;77:500–503
  18. Larsson LI. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology. 2001;108:1439–1444
  19. Larsson LI. Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand. 2001;79:567–571
  20. Larsson LI, Rettig ES, Brubaker RF. Aqueous flow in open-angle glaucoma. Arch Ophthalmol. 1995;113:283–286
  21. Larsson LI, Rettig ES, Sheridan PT, Brubaker RF. Aqueous humor dynamics in low-tension glaucoma. Am J Ophthalmol. 1993;116:590–593
  22. Liu JH, Kripke DF, Hoffman RE, et al.  Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci. 1998;39:2707–2712
  23. Liu JHK. Circadian rhythm of intraocular pressure. J Glaucoma. 1998;7:141–147
  24. McCannel CA, Heinrich SR, Brubaker RF. Acetazolamide but not timolol lowers aqueous humor flow in sleeping humans. Graefes Arch Clin Exp Ophthalmol. 1992;230:518–520
  25. Mishima HK, Kiuchi Y, Takamatsu M, et al: Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv Ophthalmol 41(Suppl 2):S139–44, 197
  26. Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens. Ophthalmology. 1993;100:1305–1311
  27. Nilsson SF, Samuelsson M, Bill A, Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989;48:707–716
  28. Orzalesi N, Rossetti L, Invernizzi T, et al.  Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566–2573
  29. Reiss GR, Lee DA, Topper JE, Brubaker RF. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci. 1984;25:776–778
  30. Stjernschantz J, Selén G, Sjöquist B, Resul B: Preclinical pharmacology of latanoprost, a phenylsubstituted PG F2α-analogue, in Samuelsson B (ed): Advances in Prostaglandin, Tromboxane, and Leukotriene Research, Vol 23. New York, Raven Press, pp 513–8
  31. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci. 1985;26:1315–1319
  32. Wildsoet C, Brown B, Swann PG. Darkness and sleep as contributing factors to diurnal variation in intraocular pressure. J Glaucoma. 1990;12:140–147
  33. Wildsoet C, Eyeson-Annan M, Brown B, et al.  Investigation of parameters influencing intraocular pressure increases during sleep. Ophthalmic Physiol Opt. 1993;13:357–365
  34. Wilensky JT. Diurnal variations in intraocular pressure. Trans Am Ophthalmol Soc. 1991;89:757–790
  35. Zeimer RC. Circadian variations in intraocular pressure. In:  Ritch R,  Shields MB,  Krupin T editor. The Glaucomas. St Louis: Mosby; 1996;p. 429–445
  36. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;111:1351–1358

☆ Dr Larsson is a consultant to Pharmacia Corp. Three of the four studies that were reviewed in the article had financial support from Pharmacia Corp. The authors reported no financial or proprietary interest in any concepts discussed or products mentioned in the article.

PII: S0039-6257(02)00296-5

Survey of Ophthalmology
Volume 47 , Pages S90-S96 , August 2002

Article Tools

* Image Usage & Resolution